| News
Botnar Research Center advancing research into coronavirus
30.03.2020
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.
3D rendering of a microscopic image of the novel coronavirus SARS-CoV-2 (img: Creativeneko/123rf)
The Botnar Research Center for Child Health (BRCCH) was founded by the University of Basel and the Swiss Federal Institute of Technology in Zurich (ETH). The University Children’s Hospital Basel (UKBB) and the Swiss Tropical and Public Health Institute (Swiss TPH), which is likewise based in Basel, are also involved with the center. BRCCH is now providing its four partner institutions with 15 million Swiss francs to facilitate research into the coronavirus, as detailed in a press release issued by the University of Basel.
The funding is to be provided by the Foundation Botnar as part of a first emergency initiative organized by the BRCCH, which was opened in 2019. Within the framework of this initiative, projects “dealing with the diagnosis and human immune response to COVID-19, as well as to projects in the fields of medical interventions and disease management” are to be supported over the next two-and-a-half years.
The BRCCH initiative will focus on two objectives: first, to come up with solutions to urgent problems in the fight against the pandemic and, second, to develop long-term approaches “so that similar situations can be better managed worldwide in the future”.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Yokogawa establishes innovation center in Allschwil
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.
Read More
Basel gains new biotech in Bright Peak
Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.
Read More
Robots from Basel set to revolutionize surgery
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.
Read More
T3 Pharma raises over 25 million Swiss francs
T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.
Read More
Versameb raises 6 million Swiss francs
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.
Read More
Genedata accelerating drug development
Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.
Read More
Basel is “probably the most productive life sciences location in the world”
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.
Read More
Basel Area cantons publish joint economic report
The cantons of Basel-Landschaft, Basel-Stadt and Jura have just published their first joint Economic Report. The fundamental environment is described as “good” in the report.
Read More
Resistell receives high-level EU grant
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.
Read More
Switzerland Innovation Park Basel Area Site Novartis Campus
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.
Read More
